Highlights der ASCO- und ESMO-Jahrestagungen 2021 zur Strahlentherapie von Kopf-Hals-Tumoren

Hecht, Markus; Grün, Jens von der; Semrau, Sabine; Müller, Sarina; Weissmann, Thomas; Gaipl, Udo S.; Iro, Heinrich; Fietkau, Rainer; Gostian, Antoniu‐Oreste

doi:10.1007/s00106-022-01150-4

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several prospective studies on head and neck cancer have found that adding PD-1/PD-L1 inhibitor (Pembrolizumab or Avelumab) to CCRT and subsequent maintenance PD-1/PD-L1 inhibitor for one year did not significantly improve survival outcomes compared to those treated with CCRT alone ( 20 , 21 ). However, patients enrolled in both studies did not receive induction therapy, therefore the response to IC and PD-1 inhibitor could not be evaluated.…”

Section: Discussionmentioning

confidence: 99%

Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Yu,

Lu,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

PurposeTo investigate the treatment response and toxicity of the combination of induction chemotherapy (IC) and PD-1 inhibitor in locally advanced nasopharyngeal carcinoma (LANPC).MethodsPatients with stage III–IVA NPC who received IC or IC + PD-1 inhibitor were included. The chi-square test and multivariate logistic regression analysis were used for statistical analysis.ResultsA total of 225 patients were identified, including 193 (85.8%) and 32 (14.2%) who received IC alone and IC + PD-1 inhibitor, respectively. The addition of PD-1 inhibitor to IC significantly improved the tumor response than those treated with IC alone. The complete response (CR), partial response, stable disease, and progressive disease rates of 4.7% vs. 31.3%, 69.4% vs. 62.5%, 24.9% vs. 6.3%, and 1.0% vs. 0% in patients receiving IC alone and IC + PD-1 inhibitor, respectively (P<0.001). The results of the multivariate logistic regression showed that receiving PD-1 inhibitor was an independent predictor influencing the CR rate of patients (odds ratio 9.814, P<0.001). The most common toxicity by using IC and PD-1 inhibitor was hematological toxicity. In terms of non-hematological toxicity, 7 (21.9%) patients experienced thyroid dysfunction and all of them were hyperthyroidism. No grade 5 toxicities were found. In those who received IC and PD-1 inhibitor, the one-year locoregional recurrence-free survival, distant metastasis-free survival, disease-free survival, and overall survival were 100%, 96.9%, 96.9%, and 100%, respectively.ConclusionThe addition of PD-1 inhibitor to IC has promise as an effective treatment approach for LANPC. More studies are expected to provide further insights into the optimal use of this treatment strategy, paving the way for more personalized and effective treatment options for patients with LANPC.

show abstract

Section: Discussionmentioning

confidence: 99%